Cash, Cash Equivalents and Marketable Securities

3 Months Ended

Mar. 31, 2022

Cash And Cash Equivalents [Abstract]

Cash, Cash Equivalents and Marketable Securities

4. Cash, Cash Equivalents and Marketable Securities

Cash, cash equivalents and marketable securities consisted of the following (in thousands):

	March 31, 2022
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Cash and cash equivalents:
Cash	$	42,703	$	—	$	—		$	42,703
Money market funds		25,506		—		—			25,506
Commercial paper		30,287		—		(2	)		30,285
U.S. government and agency securities		5,006		—		—			5,006
Total cash and cash equivalents	$	103,502	$	—	$	(2	)	$	103,500
Marketable securities:
Commercial paper	$	33,550	$	1	$	(27	)	$	33,524
U.S. government and agency securities		128,214		1		(1,001	)		127,214
Corporate debt securities		66,487		—		(693	)		65,794
Total marketable securities	$	228,251	$	2	$	(1,721	)	$	226,532

	December 31, 2021
	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Cash and cash equivalents:
Cash	$	44,499	$	—	$	—		$	44,499
Money market funds		117,023		—		—			117,023
Commercial paper		16,898		—		(1	)		16,897
Corporate debt securities		3,306		—		(1	)		3,305
Total cash and cash equivalents	$	181,726	$	—	$	(2	)	$	181,724
Marketable securities:
Commercial paper	$	34,978	$	—	$	(10	)	$	34,968
U.S. government and agency securities		85,309		1		(88	)		85,222
Corporate debt securities		53,172		4		(38	)		53,138
Total marketable securities	$	173,459	$	5	$	(136	)	$	173,328

The amortized cost and estimated fair value of our available-for-sale marketable securities by contractual maturity are summarized below as of March 31, 2022 (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Estimated Fair Value
Mature in one year or less	$	173,306	$	2	$	(709	)	$	172,599
Mature after one year through two years		54,945		—		(1,012	)		53,933
Total available-for-sale marketable securities	$	228,251	$	2	$	(1,721	)	$	226,532

None of our marketable securities were in a continuous unrealized loss position as of March 31, 2022. We review individual securities in our portfolio to determine whether a decline in a security’s fair value below the amortized cost basis is other-than-temporary. We determined that as of March 31, 2022, there were no investments in our portfolio that were other-than-temporarily impaired.